Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer

Biomaterials

Volumn 152, Issue , 2018, Pages 47-62

  Miller Kleinhenz, Jasmine ^a   Guo, Xiangxue ^a   Qian, Weiping ^a   Zhou, Hongyu ^a   Bozeman, Erica N ^a   Zhu, Lei ^a   Ji, Xin ^b   Wang, Y Andrew ^b   Styblo, Toncred ^a   O'Regan, Ruth ^c   Mao, Hui ^a   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCEAN NANOTECH LLC   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer stem cells; Chemo resistant breast cancer; Multiplexed peptide conjugated nanoparticle; uPAR; Wnt LRP receptors

Indexed keywords

CELL SIGNALING; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; ENZYME INHIBITION; IRON OXIDES; NANOMAGNETICS; NANOPARTICLES; PEPTIDES; STEM CELLS; TUMORS;

BREAST CANCER; CANCER STEM CELLS; MAGNETIC IRON OXIDE NANOPARTICLES; SIMULTANEOUS BINDINGS; SYSTEMIC ADMINISTRATION; UPAR; UROKINASE PLASMINOGEN; WNT/LRP RECEPTORS;

TARGETED DRUG DELIVERY;

APC PROTEIN; AXIN; BETA CATENIN; CD24 ANTIGEN; CYCLOPHOSPHAMIDE; DICKKOPF 1 PROTEIN; DOXORUBICIN; DRUG CARRIER; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PACLITAXEL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UROKINASE RECEPTOR; WNT PROTEIN; ANTINEOPLASTIC AGENT; FERRIC ION; FERRIC OXIDE; LRP5 PROTEIN, HUMAN; LRP6 PROTEIN, HUMAN; METAL NANOPARTICLE; PEPTIDE; UROKINASE; WNT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL INVASION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONJUGATION; CONTROLLED STUDY; DRUG TARGETING; ENCAPSULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WNT SIGNALING; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; SURFACE PROPERTY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; FERRIC COMPOUNDS; HETEROGRAFTS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; METAL NANOPARTICLES; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PARTICLE SIZE; PEPTIDES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SURFACE PROPERTIES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WNT1 PROTEIN;

EID: 85032221908     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.10.035     Document Type: Article

References (46)

1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics. CA Cancer J. Clin. 2015:65 (2012), 87–108, 10.3322/caac.21262.
2. Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., Buzdar, A.U., Singletary, S.E., Hortobagyi, G.N., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25 (2007), 4414–4422, 10.1200/JCO.2007.10.6823.
3. Visvader, J.E., Lindeman, G.J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8 (2008), 755–768, 10.1038/nrc2499.
4. Kakarala, M., Wicha, M.S., Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol.(26), 2017, 2813–2820, 10.1200/JCO.2008.16.3931.
5. Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., Hilsenbeck, S.G., Pavlick, A., Zhang, X., Chamness, G.C., Wong, H., Rosen, J., Chang, J.C., Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008), 672–679, 10.1093/jnci/djn123.
6. Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., Song, E., let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131 (2007), 1109–1123, 10.1016/j.cell.2007.10.054.
7. Davison, Z., De Blacquière, G.E., Westley, B.R., May, F.E.B., Insulin-like growth factor – dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy 1. Neoplasia 13 (2011), 504–515, 10.1593/neo.101590.
8. Lindvall, C., Bu, W., Williams, B.O., Li, Y., Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 3 (2007), 157–168, 10.1007/s12015-007-0025-3.
9. King, T.D., Suto, M.J., Li, Y., The Wnt/B-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J. Cell Biochem. 18 (2012), 13–18, 10.1002/jcb.23350.
10. Yin, S., Xu, L., Bon, R.D., Banerjee, S., Sarkar, F.H., Sethi, S., Reddy, K.B., Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther. 12 (2013), 491–498, 10.1158/1535-7163.MCT-12-1090.
11. Xu, W., Liu, Z., Yang, C., Qin, W., Shao, Z., Expression of Dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One 7 (2012), 1–7, 10.1371/journal.pone.0037624.
12. Pohl, S., Brook, N., Agostino, M., Arfuso, F., Kumar, A.P., Dharmarajan, A., Wnt signaling in triple-negative breast cancer. Oncogenesis 6 (2017), 1–12, 10.1038/oncsis.2017.14.
13. Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang, J., Doble, B., Woodgett, J., Wynshaw-boris, A., Hsieh, J., He, X., Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 375 (2008), 367–375, 10.1242/dev.013540.
14. Bahrami, A., Amerizadeh, F., Shahidsales, S., Khazaei, M., Ghayour-mobarhan, M., Sadeghnia, H.R., Maftouh, M., Hassanian, S.M., Avan, A., Therapeutic potential of targeting Wnt/B-catenin pathway in treatment of colorectal cancer: rational and progress. J. Cell Biochem. 118 (2017), 1979–1983, 10.1002/jcb.25903.
15. Blagodatski, A., Poteryaev, D., Katanaev, V.L., Targeting the Wnt pathways for therapies. Mol. Cell Ther., 2, 2014, 28, 10.1186/2052-8426-2-28.
16. Liu, C.-C., Prior, J., Piwnica-Worms, D., Bu, G., LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5136–5141, 10.1073/pnas.0911220107.
17. Tung, E.K.K., Wong, B.Y.C., Yau, T.O., Ng, I.O.L., Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One 7 (2012), 1–10, 10.1371/journal.pone.0036565.
18. Lin, C., Lu, W., Zhai, L., Bethea, T., Berry, K., Qu, Z., Waud, W.R., Li, Y., Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett. 585 (2011), 3120–3125, 10.1016/j.febslet.2011.08.046.
19. DiMeo, T.A., Anderson, K., Phadke, P., Feng, C., Perou, C.M., Naber, S., Kuperwasser, C., A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69 (2009), 5364–5373, 10.1158/0008-5472.CAN-08-4135.
20. Lu, W., Lin, C., King, T.D., Chen, H., Reynolds, R.C., Li, Y., Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal 24 (2012), 2291–2296, 10.1016/j.cellsig.2012.07.009.
21. Zhang, X., Hao, J., Development of anticancer agents targeting the Wnt/β-catenin signaling. Am. J. Cancer Res. 5 (2015), 2344–2360.
22. Hao, W., Friedman, A., Serum uPAR as biomarker in breast cancer recurrence: a mathematical model. PLoS One, 11, 2016, e0153508, 10.1371/journal.pone.0153508.
23. Huber, M.C., Mall, R., Braselmann, H., Feuchtinger, A., Molatore, S., Lindner, K., Walch, A., Gross, E., Schmitt, M., Falkenberg, N., Aubele, M., uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer, 16, 2016, 615, 10.1186/s12885-016-2663-9.
24. Jo, M., Eastman, B.M., Webb, D.L., Stoletov, K., Klemke, R., Gonias, S.L., Cell signaling by urokinase-type plasminogen activator receptor induces stem cell–like properties in breast cancer cells. Cancer Res. 70 (2011), 8948–8958, 10.1158/0008-5472.CAN-10-1936.Cell.
25. Asuthkar, S., Gondi, C.S., Nalla, A.K., Velpula, K.K., Gorantla, B., Rao, J.S., Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells. J. Biol. Chem. 287 (2012), 20576–20589, 10.1074/jbc.M112.348888.
26. Mann, B., Gelos, M., Siedow, A., Hanski, M.L., Gratchev, A., Bodmer, W.F., Moyer, M.P., Riecken, E.O., Buhr, H.J., Hanski, A.C., Target genes of β-catenin–T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Med. Sci. 96 (1999), 1603–1608, 10.1073/pnas.96.4.1603.
27. Bafico, A., Liu, G.Z., Yaniv, A., Gazit, A., Aaronson, S.A., Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 3 (2001), 683–686, 10.1038/35083081.
28. Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B.M., Delius, H., Hoppe, D., Stannek, P., Walter, C., Glinka, A., Niehrs, C., Kremen proteins are Dickkopf receptors that regulate Wnt/b -catenin signalling. Nat. Lett. 417 (2002), 6–9.
29. Wend, P., Runke, S., Wend, K., Anchondo, B., Yesayan, M., Jardon, M., Hardie, N., Loddenkemper, C., Ulasov, I., Lesniak, M.S., Wolsky, R., Bentolila, L.A., Grant, S.G., et al. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol. Med. 5 (2013), 264–279, 10.1002/emmm.201201320.
30. Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O.W., Gong, Y., Estevez, A., Zilberleyb, I., Rouge, L., Chiu, C., Wu, Y., et al. Wnt Antagonists Bind through a Short Peptide to the First β-propeller domain of LRP5/6. Structure, vol. 19, 2011, Elsevier Ltd, 1433–1442, 10.1016/j.str.2011.07.005.
31. Yang, L., Peng, X., Wang, Y.A., Wang, X., Cao, Z., Ni, C., Karna, P., Zhang, X., Wood, W.C., Gao, X., Nie, S., Mao, H., Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 15 (2009), 4722–4733, 10.1158/1078-0432.CCR-08-3289.
32. Zhang, Y., I-TASSER server for protein 3D structure prediction. BMC Bioinforma., 9, 2008, 40, 10.1186/1471-2105-9-40.
33. Roy, A., Kucukural, A., Zhang, Y., I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5 (2010), 725–738, 10.1038/nprot.2010.5.
34. Yang, L., Cao, Z., Sajja, H.K., Mao, H., Wang, L., Geng, H., Xu, H., Jiang, T., Wood, W.C., Nie, S., Wang, Y.A., Development of receptor targeted magnetic iron oxide nanoparticles for efficient drug delivery and tumor imaging. J. Biomed. Nanotechnol. 4 (2008), 439–449, 10.1166/jbn.2008.007.Development.
35. Iozzi, S., Remelli, R., Lelli, B., Diamanti, D., Pileri, S., Bracci, L., Roncarati, R., Caricasole, A., Bernocco, S., Functional characterization of a small-molecule inhibitor of the DKK1-LRP6 interaction. ISRN Mol. Biol. 2012 (2012), 1–9, 10.5402/2012/823875.
36. Mbalaviele, G., Dunstan, C.R., Sasaki, A., Williams, P.J., Mundy, G.R., Yoneda, T., E-Cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res. 56 (1996), 4063–4070.
37. Khramtsov, A.I., Khramtsova, G.F., Tretiakova, M., Huo, D., Olopade, O.I., Goss, K.H., Wnt/β-Catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176 (2010), 2911–2920, 10.2353/ajpath.2010.091125.
38. Dey, N., Barwick, B.G., Moreno, C.S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K.F., Sledge, G.W., Abramovitz, M., Bouzyk, M., De, P., et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer, 13, 2013, 537, 10.1186/1471-2407-13-537.
39. Vishnoi, M., Peddibhotla, S., Yin, W., Scamardo, A.T., George, G.C., Hong, D.S., Marchetti D, The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci. Rep. Nat. Publ. Group, 5, 2015, 17533, 10.1038/srep17533.
40. Shima, H., Yamada, A., Ishikawa, T., Endo, I., Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?. Gland. Surg. 6 (2017), 82–88, 10.21037/gs.2016.08.03.
41. Xu, H., Tian, Y., Yuan, X., Liu, Y., Wu, H., Liu, Q., Wu, G.S., Wu, K., Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther. 9 (2016), 431–444.
42. Lester, R.D., Jo, M., Montel, V., Takimoto, S., Gonias, S.L., uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178 (2007), 425–436, 10.1083/jcb.200701092.
43. Yook, J.I., Li, X., Ota, I., Hu, C., Kim, H.S., Kim, N.H., Cha, S.Y., Ryu, J.K., Choi, Y.J., Kim, J., Fearon, E.R., Weiss, S.J., A Wnt – axin2 – GSK3 β cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 8 (2006), 1398–1406, 10.1038/ncb1508.
44. Cano, A., Pérez-moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., Barrio, M.G., Portillo, F., Nieto, M.A., The transcription factor Snail controls epithelial – mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000), 76–83.
45. Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., De Herreros, A.G., The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2 (2000), 84–89.
46. Jiang, N., Huang, J., Edwards, L.J., Liu, B., Zhang, Y., Beal, C.D., Evavold, B.D., Zhu, C., Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination. Immunity 34 (2011), 13–23, 10.1016/j.immuni.2010.12.017.